CJC-1295 / Ipamorelin Peptide Therapy in Gainesville, FL

What Are CJC-1295 and Ipamorelin?

CJC-1295 is a Growth Hormone-Releasing Hormone (GHRH) analog. It signals the anterior pituitary to release growth hormone over an extended window. The version we prescribe at Bespoke is the no-DAC variant — CJC-1295 without DAC — which has a shorter half-life and produces cleaner, more physiologic GH pulses than the long-acting CJC-1295 with DAC formulation.

Ipamorelin is a Growth Hormone-Releasing Peptide (GHRP) and selective ghrelin receptor agonist. It triggers an immediate, focused GH pulse without the cortisol or prolactin elevations seen with older GHRPs (GHRP-2, GHRP-6, hexarelin).

Why Stack Them Together?

The two peptides act on different receptor systems and reinforce each other:

• CJC-1295 raises the baseline GH ceiling by stimulating GHRH receptors.
• Ipamorelin drives a sharper, immediate GH spike via the ghrelin receptor.
• Combined, the two produce a stronger, longer GH pulse than either alone — mimicking the body’s natural overnight release pattern.
• Because both work through your own pituitary, the negative-feedback loop stays intact — meaning the protocol does not shut down your endogenous GH axis the way exogenous HGH does.

Clinical Benefits Patients Report

Documented or commonly reported benefits at therapeutic doses (10–16 weeks):

• Improved sleep depth and recovery quality
• Lean-mass support during caloric deficit and resistance training
• Body-composition improvements (visceral fat reduction, lean tissue retention)
• Skin elasticity and collagen support
• Joint comfort and connective-tissue recovery
• Energy stability and exercise tolerance

Outcomes vary by baseline labs, body composition, sleep, and adherence. Bespoke screens for hormone interactions, cancer history, and pituitary contraindications before prescribing.

Bespoke’s Protocol

Every CJC-1295 / Ipamorelin protocol at Bespoke is individualized after intake labs and physician evaluation. Standard framework:

• Compounded blend — CJC-1295 (no DAC) + Ipamorelin in a single subcutaneous vial, sourced from a 503A licensed pharmacy partner. Compounded preparations are not FDA approved.
• Dosing window — Subcutaneous injection 5 nights/week, dosed at bedtime to align with your natural overnight GH pulse.
• Cycle length — Standard 12–16 week initial cycle with a 4-week off-cycle to preserve receptor sensitivity.
• Lab monitoring — Baseline + mid-cycle IGF-1, fasting glucose, A1c, and where indicated, cortisol and thyroid panels.
• Physician follow-up — Dr. Indianos personally reviews your IGF-1 trajectory and adjusts dosing if needed.

Who Is a Candidate?

CJC-1295 / Ipamorelin is generally appropriate for adults ≥ 30 with documented age-related GH decline, sleep dysfunction, slow recovery, or recomposition goals who have:

• No active or recent malignancy
• Controlled glucose metabolism (peptides can affect insulin sensitivity)
• No known pituitary pathology
• Realistic expectations — this is a 12–16 week investment, not an overnight result

Patients with diabetes, active cancer history, or pregnancy/breastfeeding are not candidates. We screen carefully at intake.

CJC/Ipamorelin vs. Sermorelin vs. HGH

All three approaches raise IGF-1, but they differ meaningfully:

• Sermorelin — GHRH analog only. Gentle, well-tolerated, often a starter option. Read more about sermorelin →
• CJC-1295 / Ipamorelin (this page) — Two-mechanism stack. Stronger GH amplitude than sermorelin alone. Preferred for body-composition and recovery focus.
• Exogenous HGH — Direct synthetic growth hormone. Bespoke does not prescribe HGH for non-FDA-indicated use; the peptide approach preserves your own endocrine feedback loop and avoids the regulatory and side-effect profile of HGH.

Side Effects & Safety

When properly prescribed and dosed, CJC-1295 / Ipamorelin has a strong safety record. Reported side effects are typically mild:

• Injection-site warmth or redness (resolves within hours)
• Transient flushing or head-rush in the first weeks
• Increased appetite (Ipamorelin’s ghrelin agonism)
• Vivid dreams in the first 1–2 weeks of dosing

Rare but possible: water retention, mild fatigue at higher doses, transient blood-sugar effects. These are why we monitor IGF-1, fasting glucose, and A1c during the cycle.